PL3428274T3 - Wykorzystanie domen białkowych oddziałujących na nukleosomy w celu wzmocnienia celowanej modyfikacji genomu - Google Patents

Wykorzystanie domen białkowych oddziałujących na nukleosomy w celu wzmocnienia celowanej modyfikacji genomu

Info

Publication number
PL3428274T3
PL3428274T3 PL18182999T PL18182999T PL3428274T3 PL 3428274 T3 PL3428274 T3 PL 3428274T3 PL 18182999 T PL18182999 T PL 18182999T PL 18182999 T PL18182999 T PL 18182999T PL 3428274 T3 PL3428274 T3 PL 3428274T3
Authority
PL
Poland
Prior art keywords
interacting protein
protein domains
genome modification
targeted genome
enhance targeted
Prior art date
Application number
PL18182999T
Other languages
English (en)
Inventor
Fuqiang Chen
Xiao DING
Yongmei FENG
Gregory D. Davis
Original Assignee
Sigma-Aldrich Co. Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Aldrich Co. Llc filed Critical Sigma-Aldrich Co. Llc
Publication of PL3428274T3 publication Critical patent/PL3428274T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL18182999T 2017-07-11 2018-07-11 Wykorzystanie domen białkowych oddziałujących na nukleosomy w celu wzmocnienia celowanej modyfikacji genomu PL3428274T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762531222P 2017-07-11 2017-07-11
EP18182999.5A EP3428274B1 (en) 2017-07-11 2018-07-11 Using nucleosome interacting protein domains to enhance targeted genome modification

Publications (1)

Publication Number Publication Date
PL3428274T3 true PL3428274T3 (pl) 2022-01-03

Family

ID=62916578

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21193940.0T PL3988656T3 (pl) 2017-07-11 2018-07-11 Wykorzystanie domen białkowych oddziałujących na nukleosomy w celu wzmocnienia celowanej modyfikacji genomu
PL18182999T PL3428274T3 (pl) 2017-07-11 2018-07-11 Wykorzystanie domen białkowych oddziałujących na nukleosomy w celu wzmocnienia celowanej modyfikacji genomu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL21193940.0T PL3988656T3 (pl) 2017-07-11 2018-07-11 Wykorzystanie domen białkowych oddziałujących na nukleosomy w celu wzmocnienia celowanej modyfikacji genomu

Country Status (17)

Country Link
US (3) US10604752B2 (pl)
EP (2) EP3428274B1 (pl)
JP (3) JP6994560B2 (pl)
KR (3) KR20240046316A (pl)
CN (1) CN111183226A (pl)
AU (3) AU2018299995B2 (pl)
CA (1) CA3066790C (pl)
DK (2) DK3428274T3 (pl)
ES (2) ES2901629T3 (pl)
FI (1) FI3988656T3 (pl)
GB (3) GB2567917B (pl)
IL (2) IL309801B2 (pl)
LT (2) LT3428274T (pl)
PL (2) PL3988656T3 (pl)
PT (2) PT3428274T (pl)
SG (1) SG11201911864PA (pl)
WO (1) WO2019014230A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3443081A4 (en) 2016-04-13 2019-10-30 Duke University CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
KR20240046316A (ko) 2017-07-11 2024-04-08 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
JP7109547B2 (ja) * 2018-02-15 2022-07-29 シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー 真核ゲノム修飾のための操作されたＣａｓ９システム
GB2587970B (en) 2018-04-19 2023-02-08 Univ California Compositions and methods for gene editing
WO2020036653A2 (en) * 2018-04-25 2020-02-20 The Regents Of The University Of California Improved method for homology directed repair in cells
BR112020024736A2 (pt) 2018-06-04 2021-03-23 University Of Copenhagen endonucleases cpf1 mutantes
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
WO2020187272A1 (zh) * 2019-03-19 2020-09-24 上海邦耀生物科技有限公司 一种用于基因治疗的融合蛋白及其应用
CN111718420B (zh) * 2019-03-19 2021-09-14 华东师范大学 一种用于基因治疗的融合蛋白及其应用
CN111718418B (zh) * 2019-03-19 2021-08-27 华东师范大学 一种增强基因编辑的融合蛋白及其应用
SG11202111982UA (en) * 2019-05-13 2021-11-29 Emd Millipore Corp Synthetic self-replicating rna vectors encoding crispr proteins and uses thereof
AU2020345830A1 (en) * 2019-09-09 2022-03-24 Beam Therapeutics Inc. Novel CRISPR enzymes, methods, systems and uses thereof
WO2021224506A1 (en) * 2020-05-08 2021-11-11 Universitat Pompeu Fabra Crispr-cas homology directed repair enhancer
CA3182672A1 (en) * 2020-05-08 2021-11-11 Duke University Chromatin remodelers to enhance targeted gene activation
WO2022059928A1 (ko) * 2020-09-21 2022-03-24 고려대학교 산학협력단 신규의 개량된 염기 편집 또는 교정용 융합단백질 및 이의 용도
EP4230737A4 (en) * 2020-09-21 2024-07-24 Korea University Research and Business Foundation NOVEL IMPROVED BASIC EDITING OR REVISION FUSION PROTEIN AND USE THEREOF
EP4230738A4 (en) * 2020-09-24 2024-11-20 Korea University Research and Business Foundation Prime editing-based gene editing composition with enhanced editing efficiency and use thereof
MX2023005150A (es) * 2020-11-06 2023-05-26 Pairwise Plants Services Inc Composiciones y metodos para el reemplazo de alelos con adn codificado por arn.
CN114507689B (zh) * 2022-01-27 2024-01-16 山东大学 一种提高真核生物基因编辑效率的方法及其应用
CN115716880A (zh) * 2022-12-07 2023-02-28 云舟生物科技(广州)股份有限公司 一种核定位荧光蛋白及其应用
CN115948465B (zh) * 2022-12-16 2025-09-19 中国农业科学院北京畜牧兽医研究所 猪hat1基因修饰系统及应用
WO2026097018A1 (en) * 2024-11-04 2026-05-07 Intellia Therapeutics, Inc. Polypeptides, polynucleotides, compositions, and methods for genome editing involving chromatin remodelers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005010A (es) 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
US20050003403A1 (en) 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
EP2834357B1 (en) 2012-04-04 2017-12-27 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
JP2015527889A (ja) * 2012-07-25 2015-09-24 ザ ブロード インスティテュート， インコーポレイテッド 誘導可能なｄｎａ結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用
EP3135765A1 (en) 2012-12-06 2017-03-01 Sigma-Aldrich Co. LLC Crispr-based genome modification and regulation
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US10378027B2 (en) * 2013-03-15 2019-08-13 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
WO2015048577A2 (en) * 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
US10570418B2 (en) * 2014-09-02 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification
WO2016049251A1 (en) * 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US10190106B2 (en) 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
AU2015370435A1 (en) 2014-12-24 2017-06-15 Dana-Farber Cancer Institute, Inc. Systems and methods for genome modification and regulation
ES2886599T3 (es) * 2015-06-17 2021-12-20 Poseida Therapeutics Inc Composiciones y métodos para dirigir proteínas a loci específicos en el genoma
EP3313445A1 (en) 2015-06-24 2018-05-02 Sigma Aldrich Co. LLC Cell cycle dependent genome regulation and modification
CN107922953B (zh) 2015-08-20 2022-03-04 应用干细胞有限公司 提高基因编辑效率的核酸酶
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
KR20240046316A (ko) 2017-07-11 2024-04-08 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용

Also Published As

Publication number Publication date
GB2593814A (en) 2021-10-06
LT3428274T (lt) 2021-11-25
AU2022200851A1 (en) 2022-03-03
EP3428274B1 (en) 2021-10-13
GB202114520D0 (en) 2021-11-24
JP6994560B2 (ja) 2022-02-21
EP3988656A1 (en) 2022-04-27
US20210024916A1 (en) 2021-01-28
EP3988656B9 (en) 2024-11-27
ES2901629T3 (es) 2022-03-23
FI3988656T3 (fi) 2024-10-29
GB2598847B (en) 2022-06-01
IL271197B1 (en) 2024-02-01
GB2598847A (en) 2022-03-16
GB2567917B (en) 2021-05-12
KR20240046316A (ko) 2024-04-08
GB2593814B (en) 2022-01-05
IL309801A (en) 2024-02-01
LT3988656T (lt) 2024-11-11
JP2020530287A (ja) 2020-10-22
EP3428274A1 (en) 2019-01-16
AU2022200851B2 (en) 2023-12-14
AU2018299995A1 (en) 2020-01-02
US20190017042A1 (en) 2019-01-17
KR102523217B1 (ko) 2023-04-20
JP7469285B2 (ja) 2024-04-16
CA3066790A1 (en) 2019-01-17
US12065642B2 (en) 2024-08-20
WO2019014230A1 (en) 2019-01-17
KR102655021B1 (ko) 2024-04-04
IL309801B1 (en) 2024-08-01
CA3066790C (en) 2023-07-18
US10604752B2 (en) 2020-03-31
DK3988656T3 (da) 2024-11-11
US12221606B2 (en) 2025-02-11
AU2021245148B2 (en) 2024-01-04
CN111183226A (zh) 2020-05-19
GB2567917A (en) 2019-05-01
KR20230053732A (ko) 2023-04-21
ES2997490T3 (en) 2025-02-17
PT3428274T (pt) 2021-11-05
GB201811358D0 (en) 2018-08-29
PT3988656T (pt) 2024-11-07
IL271197A (en) 2020-01-30
AU2021245148A1 (en) 2021-11-04
JP2024096783A (ja) 2024-07-17
KR20200021529A (ko) 2020-02-28
US20200208135A1 (en) 2020-07-02
IL309801B2 (en) 2024-12-01
EP3988656B1 (en) 2024-09-18
JP2022046532A (ja) 2022-03-23
PL3988656T3 (pl) 2024-12-16
DK3428274T3 (da) 2021-11-15
IL271197B2 (en) 2024-06-01
SG11201911864PA (en) 2020-01-30
GB202103935D0 (en) 2021-05-05
AU2018299995B2 (en) 2021-10-28
BR112019028261A2 (pt) 2020-07-14

Similar Documents

Publication Publication Date Title
IL271197A (en) Using protein domains that interact with the nucleosome to enhance targeted genome modification
IL295358A (en) Using programmable dna binding proteins to enhance targeted genome modification
IL268894A (en) Medical RNA
IL272514A (en) Compositions and methods for modifying genomes
IL290733A (en) Conjugations of quaternary tubulin compounds
SG11201707663SA (en) Lyophilization of rna
ZA201805634B (en) Conjugate of therapeutic enzymes
ZA201703163B (en) Rna guided eradication of human jc virus and other polyomaviruses
MA43570A (fr) Thérapie génique pour traiter l'hypercholestérolémie familiale
EP3876936A4 (en) PROCEDURE FOR SHRINKING PITITUNITIAL TUMORS
GB201711481D0 (en) Protein purification
EP3261631C0 (en) INHIBITION OF OLIG2 ACTIVITY
EP3076985C0 (en) COMPOSITION COMPRISING PROBIOTICS CAPABLE OF OVEREXPRESSING CLPB PROTEIN FOR USE IN THE TREATMENT OF OBESITY
LT3368044T (lt) Kepenų steatozės, susijusios su oligo-ovuliacija, gydymas
EP3595688A4 (en) GENE THERAPY TO TREAT FAMILY HYPERCHOLESTEROLEMIA
EP3302557A4 (en) INCREASING THE THERAPEUTIC EFFICACY OF AN IMMUNE CHECKPOINT HEMMER
SG10201910999TA (en) Native protein purification technology
GB201622116D0 (en) Treatment of liver disease
GB201704922D0 (en) Methods of protein stapling
EP3302067A4 (en) Use of proteins to control molluscs
GB201521547D0 (en) New therapeutic uses of enzyme inhibitors
GB201521541D0 (en) New therapeutic uses of enzyme inhibitors